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1. Introduction 
 
Lactose (4-(β-D-galactopyranosyl)-D-glucopyranose) is a disaccharide, which is 
not only present in milk and dairy products, but also in many pharmaceutical 
formulations. It is hydrolyzed by the enzyme Lactase (Lactase-phlorizin hydrolase; 
LPH; ß-galactosidase) into glucose and galactose, which can be absorbed and 
transported into the blood [1]. LPH is located at the brush border of enterocytes. 
The inability to metabolize lactose because of the absence of the enzyme lactase 
is called lactose intolerance. It is estimated that 75 - 90% of birth lactase levels are 
lost by most people after weaning and the enzyme level decreases continuously 
during the whole life. The prevalence of lactase deficiency ranges widely with the 
ethnic background from 2 - 15% among Northern Europeans to 95 - 100% among 
Asians [2]. The undigested lactose adsorbs water and causes an increase of the 
osmotic pressure. Furthermore, fermentation of lactose by bacteria in the colon 
leads to the production of hydrogen, methane, and carbon dioxide. The typical 
clinical symptoms of lactose intolerance are abdominal pain, distension, flatulence 
and diarrhea, as well as systemic symptoms caused by the toxic fermentation 
metabolites [1, 2].  
Nowadays, lactose intolerance is usually controlled by strict adherence to a 
lactose-free or lactose-reduced diet. However, the main disadvantage of avoiding 
dairy products is to lose a major source of calcium and protein. As an alternative, 
capsules or tablets containing microbial-derived ß-galactosidase are available. 
Although they significantly reduce the clinical symptoms of lactose intolerance, the 
most inconvenient point is that by reason of their short-acting effect, patients have 
to take those formulations directly before or together with a lactose containing diet 
[2]. 
Therefore, the present work aimed at an innovative peroral lactase formulation 
which enables a longer action and thus offers a better patient compliance by 
reducing the dosage frequency. At this, microparticles were manufactured from 
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the biocompatible and biodegradable copolymer poly (D,L-lactide-co-glycolide) 
(PLGA) [3 - 5] and surface-functionalized with β-galactosidase and wheat germ 
agglutinin (WGA). Due to their pH optima of 6.0 - 8.0 [6] and 7.0 - 7.5 [7], 
respectively, β-galactosidase from Escherichia coli and Kluyveromyces lactis were 
used, which approach the physiological pH in the target area. The lectin WGA 
from Triticum vulgare was applied as a targeter to prolong the residence time in 
the gastrointestinal tract by adhering to the gastrointestinal mucus and the 
glycocalyx of human intestinal epithelial cells due to specific binding to 
N-acetyl-D-glucosamine and sialic acid [3, 8, 9]. For the presented study, 
β-galactosidase/WGA-grafted PLGA microparticles were prepared, their 
enzymatic activity and their binding to Caco-2 cells, which represent a 
well-established model for the human intestinal epithelium, were assessed. 
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2. Background 
 
2.1 Lactose Intolerance 
 
Lactose intolerance is the inability to digest lactose, because of low levels or 
deficiency of lactase enzyme in the brush border of the intestinal epithelium [1]. It 
has been recognized since the time of Hippocrates and investigated scientifically 
since about 50 years [2]. The three main types are primary, secondary, and 
congenital lactose intolerance. The primary form is a common inherited disorder 
which is characterized by a continuous decrease of lactase levels after weaning. 
Secondary intolerance may be caused by injuries of the intestinal mucosa, by 
reductions of the functional mucosal surface area or by multiple viral syndromes. 
Congenital lactose intolerance is an extremely rare condition, which is 
characterized by a lifelong total lack of lactase [1].  
In primary lactase deficiency, most people lose 75% - 90% of their birth lactase 
levels in early childhood, followed by a further decline during lifetime. The 
prevalence of this type of lactase intolerance depends on the ethnic background. 
By contrast to 2% - 15% among Northern Europeans, 95% - 100% of Asians are 
affected [2].  
When lactose cannot be broken down in the small intestine, it increases the 
osmotic pressure, which leads to the attraction of fluid into the bowel lumen. When 
the undigested lactose reaches the colon, it is fermented by bacteria that produce 
hydrogen, methane, and carbon dioxide. The most important clinical symptoms of 
lactose intolerance such as abdominal pain, distension, boborygmi, flatulence and 
diarrhoea typically occur between 30 minutes and 2 hours after the intake of 
lactose. Other gastrointestinal symptoms include constipation, nausea and 
vomiting. Potentially toxic fermentation metabolites may affect ionic signaling 
pathways in the heart, the nervous system, and the immune system, and induce 
systemic symptoms such as headaches, light headedness and muscle pain [1, 2]. 
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For diagnosis, the most common lactose tolerance test is the hydrogen breath test. 
At this, the breath hydrogen levels are measured before and after oral 
administration of a 50 g bolus of lactose. Moreover, the measurement of stool pH 
or small-bowel biopsies will also elucidate problems with the digestion of lactose 
[1]. 
Primary lactose intolerance is usually controlled by a lactose-free or 
lactose-reduced diet. However, the elimination of dairy products might provoke a 
lack of calcium. Marketed lactase preparations such as Lactaid® or Lactrase®, 
which reduce the gastrointestinal symptoms upon lactose intake, may allow 
patients to consume dairy products [1]. 
 
2.2 ß-Galactosidase 
 
Lactase (Lactase-phlorizin hydrolase; LPH; ß-galactosidase) is localized at the 
intestinal brush border [3], and catalyses the hydrolysis of lactose into glucose 
and galactose [4]. The enzyme also possesses a transferase activity and 
catalyses the formation of galacto-oligosaccharides [5] (Figure 1). 
O
O
O
O O
OO
O +
Allolactose
Galactose Glucose
H2O
Lactase
H2OLactase
Lactase
 
Figure 1: Enzymatic cleavage of lactose by lactase 
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Lactase has been detected in numerous microorganisms, animals and plants [6]. 
For the production of ß-galactosidase, microbial sources have numerous 
advantages, for example easy handling and high production yield [4].  
The temperature optimum, pH optimum, and cofactors vary depending on the 
enzyme source. For example, the pH-optimum of lactase from K. lactis is 6.5 - 7.5, 
and 6.0 - 8.0 for Escherichia coli. The temperature optima for K. lactis and E. coli 
are 30°C - 35°C and 35°C, respectively [7]. The presence of Mn2+ and Mg2+ ions 
increases stability of lactase [6 - 9]. The residual enzyme activity is also influenced 
by the presence of glucose and galactose [4, 5, 8].The most extensively 
investigated β-galactosidase is that derived from E. coli, a product of the lacZ 
operon, and exhibits a molecular weight of 465000 Da. This enzyme is a tetramer 
of four identical 1023 - amino acid chains, each consisting of five domains [10]. In 
contrast to the enzyme from E. coli, ß-galactosidase from Aspergillus niger, A. 
oryzae, Kluyveromyces lactis, and K. fragilis are used in the food industry 
because of their GRAS-status (generally recognized as safe) [5]. Among these, 
the commercial products Lactozym® and Maxilact® from K. fragilis and K. lactis are 
frequently used [9]. 
ß-Galactosidase is mainly applied in the health and food technology. Firstly, it is 
used for lactase substitution in lactose intolerant patients. Secondly, the 
enzyme-aided lactose hydrolysis is applied for preparation of lactose-reduced milk, 
cheese and yoghurt. Lactase can be also used for lactose hydrolysis in whey, 
which is a by-product in cheese production [4, 5]. 
Because of the high costs of ß-galactosidase, several immobilization methods are 
developed to allow for prolonged or repeated use. Enzyme can either be 
entrapped in gels or immobilized by physical adsorption or covalent binding to 
water-insoluble carriers. For the latter approach, the enzyme is conjugated to the 
carrier via functional groups that are not essential for the catalytic activity. At this, 
cross-linkers like glutaraldehyde or carbodiimides may be used [4, 5]. 
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2.3 Drug Targeting 
 
The aim of drug targeting is to transport drugs as exclusively as possible to the 
therapeutic target [11 - 13]. 
The most important strategies can be divided into three types: passive, active, and 
physical targeting.  
For passive targeting, physiological characteristics of the target tissue are 
exploited. The most prominent example is the enhanced permeation and retention 
(EPR) effect, which relies on the increased capillary permeability in quickly 
proliferating tumors or other types of diseased tissue [12, 13]. 
For active targeting, the drug or drug carrier is conjugated with a ligand, which 
specifically binds to certain structures on the cell surface, such as receptors or 
adhesion proteins [12, 13]. 
Physical targeting is based on non-physiological pH values or temperatures in the 
target tissue. For example, it has been observed that tumor tissue often reveals a 
lower pH or a higher temperature. When the carriers are sensitive to these stimuli, 
the therapeutic agent is released at its target. A very special example for this type 
of targeting is magnetic targeting. At this, magnetic carriers are transported to their 
targets with the aid of an externally applied magnetic field [13]. 
 
Wheat Germ Agglutinin 
Wheat germ agglutinin (WGA) is the lectin derived from Triticum vulgare. Lectins 
are proteins or glycoproteins, which specifically bind to certain mono- or 
oligosaccharides. WGA is a dimeric protein, which contains four hevein domains, 
and specifically binds to sialic acid and N-acetylglucosamine [14, 15].  
The biorecognition between lectin-mediated drug delivery systems and 
glycosylated structures in the intestine may be exploited to improve the efficacy of 
poorly absorbable drugs. Each mammalian cell possesses a carbohydrate layer, 
the so-called glycocalyx, which is built up of the oligosaccharide moieties of 
BACKGROUND 
12 
proteoglycans, glycolipids and glycoproteins that are anchored in the lipid bilayer 
of the cell membrane. In the intestine, lectins may bind to carbohydrates in the 
mucus gel layer, or in the glycocalyx of the underlying cells. WGA-binding is 
strongly reduced at acidic pH. Therefore, there is very few binding to the gastric 
mucus. For poorly resorbable drugs, lectin-targeting may shorten the diffusional 
pathway of the drug and an increased concentration gradient, which is expected 
to result in improved bioavailability. Interestingly, the glycosylated extracellular 
domain 3 of the epidermal growth factor (EGF) receptor is involved in 
WGA-binding. Due to the up regulated expression of EGF-receptors in some 
tumors, this approach might also be applicable in cancer therapy. The intracellular 
uptake of WGA is an energy-dependent process. At 4°C, the lectin only binds to 
the cell surface, while at 37°C the lectin binding to the surface may be followed by 
internalization. At least 60% of the WGA enter the lysosomal route after uptake in 
the cells [14 - 17].  
Because of the cytoadhesive and cytoinvasive characteristics of this lectin, which 
offers advantages for drug delivery or vaccination purposes, there are two 
strategies for the design of WGA-functionalized formulations: i) lectin prodrugs, 
which are composed of the lectin, a spacer and the drug; ii) lectin-grafted carrier 
systems, such as microparticles, liposomes or nanoparticles. The latter approach 
is especially interesting for the presented work which deals with WGA-grafted 
microparticles [14, 15]. 
 
2.4 Poly (D, L-lactide-co-glycolide) Particles 
 
OH
O
O
O
H
x
 
y
 
O  
Figure 2: Structure of PLGA 
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Poly (D,L-lactide-co-glycolide) (PLGA) is a copolymer of lactide and glycolide 
(Figure 2), which is biocompatible and biodegradable. Moreover, it is approved by 
the US Food and Drug Administration (FDA) for drug delivery. Thus, numerous 
active pharmaceutical ingredients such as proteins, peptides, vaccines, genes, 
antigens, and growth factors have been encapsulated into 
PLGA-nano/microparticles [18, 19]. 
The physical, chemical, and biological properties of PLGA affect the mechanical 
strength, the characteristics of the drug formulation and the drug release from the 
polymer matrix. Therefore, the intrinsic viscosity related to the molecular weights 
is usually characterized in commercial products. Furthermore, the crystallinity of 
the polymers, which depends on the type and the molar ratio of the two monomer 
components, affects the biodegradation rate and the capacity to undergo 
hydrolysis. The commonly used PLGA polymers, which contain a 50:50 ratio of 
lactic and glycolic acid, are hydrolyzed faster than those with a higher proportion 
of either of the two components. The glass transition temperature of PLGA is 
slightly above the physiological temperature depending on the copolymer 
composition and molecular weight. Upon degradation, lactic and glycolic acid are 
formed. A three phase mechanism of the hydrolytic degradation is proposed: firstly, 
the molecular weight of PLGA decreases significantly; secondly, soluble 
oligomeric and monomer products are formed; finally, the polymer is completely 
solubilized [19]. 
Three important basic methods for the production of PLGA-particles are known, 
the solvent evaporation technique, phase separation methods and spray drying. 
For the solvent evaporation technique, an active pharmaceutical ingredient is 
either dissolved in an organic solution of PLGA (single emulsion technique) or 
dissolved in an aqueous solution and dispersed in an organic PLGA phase 
(double emulsion technique). This organic solution or W/O emulsion is then 
emulsified in an outer aqueous phase, which results in the formation of an O/W 
single emulsion or a W/O/W double emulsion, respectively. Subsequently, the 
organic solvent is allowed to evaporate and the liquid droplets are hardened to 
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become solid particles. While the solvent evaporation technique is based on the 
precipitation of PLGA upon solvent extraction, phase separation techniques are 
based on the addition of a non-solvent. By contrast, spray dried particles are 
prepared by the atomizing a PLGA solution into a stream of warm air. The liquid 
droplets are dried in the air stream and the resulting particles are collected [18, 
19]. 
 
2.5 Conjugation Techniques 
 
2.5.1 Carbodiimide Method 
 
Carbodiimides are probably the most popular zero-length cross-linkers. They 
mediate the formation of amid linkages between carboxylic and primary amine 
groups or phosphoramidate linkages between phosphates and amines. 
Carboxylic groups react with N-substituted carbodiimides to form a highly active 
O-acylisourea intermediate, which can react with a nucleophile such as a primary 
amine to form a stable amide bond yielding isourea as a by-product. The optimal 
reaction medium is at a pH between 4.5 and 7.5. 
For the present work, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDAC) 
was used (Figure 3). The reagent is water-soluble, should be dissolved rapidly 
and used immediately to prevent extensive loss of activity [20]. 
 
N
N N
+
CH
3
CH
3
CH
3
Cl
H
 
Figure 3: Structure of EDAC 
 
N-Hydroxysuccinimide (NHS) or N-Hydroxysulfosuccinimide (sulfo-NHS) is added 
to the EDAC-reaction in order to increase the stability of the active intermediate 
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(O-acylisourea), which is rapidly hydrolyzed in aqueous environment. The 
hydroxyl group of NHS or sulfo-NHS can easily react with the active-ester to form 
a NHS-ester intermediate with a longer half-life in the range of some hours. 
Moreover, when using NHS the reaction can be performed in two steps. In the first 
step, the carboxylic groups are activated with EDAC/NHS. After removal of 
excessive coupling reagents by washing, the amine component is added and 
allowed to react with the active ester. This offers the advantage that the coupling 
of proteins, which contain carboxylate and amine groups, may be improved by 
avoiding the cross-linking of protein molecules with each other. Furthermore, the 
addition of NHS may improve the efficiency of the reaction [20] (Figure 4). 
O
O
N
N N
+
CH
3
CH
3
CH
3
Cl
H
Cl
H
O
O
CH
3
N N
+
CH
3
CH
3
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N OO
O
N
O
O
O
O
N OO
O
N
O
N
+
HR
+
R
H
R
H
R
R'
H
H3 R'
Carboxylic Acid EDAC
o-Acylisourea active intermediate
NHS
NHS
Amide bond formation
Primary amine containing molecule
NHS Ester intermediate
 
Figure 4: Reaction scheme of the carbodiimide method using EDAC and NHS 
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2.5.2 Glutaraldehyde Method 
 
Today, glutaraldehyde is the most important bis-aldehyde homobifunctional 
cross-linker. The cross-linking process between amine-containing molecules is 
believed to proceed by a number of mechanisms, such as Schiff base formation or 
a Michael-type addition reaction at points of double-bond unsaturation created by 
polymerization (Figure 5). In aqueous solutions at alkaline pH, α,β-unsaturated 
glutaraldehyde polymers are formed by aldol condensation. They are highly 
reactive towards nucleophiles, especially primary amines. To avoid formation of 
high-molecular-weight conjugates due to uncontrollable polymerization during the 
cross-linking process, a two-step procedure is often employed. Firstly, one 
amine-containing molecule is activated with glutaraldehyde. Upon removal of the 
excess reagent, the second amine-containing molecule is added to enable the 
final conjugation [20].   
 
Michael-type addition reaction 
O
HO
H
O H O H
O
H
O H O H
O
HN
R NH2
+
α ,β - Unsatuerated Aldehyde Polymer
R
H
Double bonds with numerous terminal formyl groups  
Figure 5: Reaction scheme of glutaraldehyde as a homobifunctional cross-linker 
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3. Materials and Methods 
 
3.1 Materials  
See Chapter 6 (Attachment A). 
 
3.2 Preparation of PLGA-Microparticles  
See Chapter 6 (Attachment A). 
 
3.3 Characterization of PLGA-Microparticles 
 
3.3.1 Laser Diffraction 
 
The particle size distribution was measured within a range of 0.1 µm to 45 µm on 
a Shimadzu® Laser Diffraction Particle Size Analyzer SALD-1100 (Shimadzu, 
Kyoto, Japan) applying the Mie theory. A laser light beam crosses a particle 
suspension. Depending on the different particle sizes, the light is scattered in 
different angles. Upon detection of the scattered light, the particle size distribution 
is calculated. 
 
3.3.2 Flow Cytometry 
 
The particle size distribution and the particle granularity were examined using a 
Coulter® EPICS® XL-MCL™ Flow Cytometer (GMI, Minnesota, USA). The forward 
scatter (FS) indicated the particle size, while the side scatter (SS) gave 
information about the particle granularity. 2 µl to 5 µl of the particle suspension 
were mixed with 1 ml particle-free 0.2% aqueous Tween® 20.  
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3.3.3 Scanning Electron Microscopy (SEM)  
Spray-dried particles were raised on a specimen holder, sputter-coated with gold 
and imaged in high vacuum with an accelerating voltage 15 kV using a PHILIPS 
XL-30 ESEM scanning electron microscope. 
 
3.4 Enzymatic Assay of ß-Galactosidase 
See Chapter 6 (Attachment A). 
 
3.5 Preparation of Fluorescein-labeled E.coli 
ß-Galactosidase 
 
3.5.1 Coupling of FITC to E.coli ß-Galactosidase 
 
2 mg β-Galactosidase from Escherichia coli (Grade VI, lyophilized powder, 
250-600 units/mg protein, purchased from Sigma Aldrich, Vienna, Austria) were 
dissolved in 1 ml 0.1M Na2CO3 pH 9.0, mixed with 50 µl of a freshly prepared 
solution of FITC (1 mg/ml in DMSO) and incubated end-over-end overnight at 4°C 
under light protection. After addition of 10 µl NH4Cl solution (150 mg/ml) the 
mixture was incubated for 2 h at 4°C. Finally, excess reagents were removed by 
gel filtration and affinity chromatography. 
 
3.5.2 Purification 
 
3.5.2.1 Gel Filtration 
 
Gel filtration separates molecules according to differences in size as they pass a 
gel filtration medium packed in a column. Unlike ion exchange or affinity 
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chromatography, molecules do not bind to the chromatography medium. Gel 
filtration is well suited for biomolecules that may be sensitive to changes in pH, 
concentration of metal ions or co-factors and harsh environmental conditions. 
Purified proteins can be collected in any chosen buffer [1]. 
Excess FITC was removed using a PD-10 Desalting column (Amersham 
Biosciences, Buckinghamshire, UK) filled with Sephadex G-25 with a particle size 
range of 85-260 µm and an exclusion limit of 5 kDa. The matrix is stable in all 
commonly used buffers between pH 2 and 13. 
Initially, the PD-10 column was equilibrated with 20mM HEPES/NaOH pH 7.2 
buffer (25 ml). Subsequently, the FITC-ß-galactosidase solution was applied. The 
enzyme was eluted with 20mM HEPES/NaOH pH 7.2 buffer at a rate of 20 drops 
per min. The eluate was collected in 20 fractions of 1 ml each.  
 
3.5.2.2 Affinity Chromatography 
 
Affinity chromatography separates proteins on the basis of a reversible interaction 
between a molecule and a specific ligand that is coupled to a matrix. The 
technique offers high selectivity, hence high resolution, and usually high capacity 
for the molecules of interest. Purification can be in the order of several 
thousand-fold and recoveries of active material are generally high [2]. 
4-Aminophenyl-β-D-thiogalactopyranoside-Agarose 4B (APTG-agarose; Sigma 
Aldrich, Vienna, Austria) can be used for the purification of ß-galactosidase [3]. 
After binding to the substrate analogue APTG the enzyme can be eluted with an 
appropriate buffer. 1 ml of APTG-agarose suspension was filled into a small 
chromatography column. After equilibration with 20mM HEPES/NaOH pH 7.2 
buffer (10 ml), 500 µl of the sample solution were applied at the head of the 
column to enable the binding of ß-galactosidase. Contaminants were removed by 
washing with 20mM HEPES/NaOH pH 7.2 buffer (10 ml). Finally, the enzyme was 
eluted with an elution buffer (200mM lactose buffer; 0.1M borate/NaOH buffer pH 
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10; 0.8M Na2CO3/NaOH buffer pH 10) and separately collected in fractions of 0.5 
ml each.  
To enable repeated use, the column was washed with 0.1M Borax pH 10 buffer (5 
ml), equilibrated with 20mM HEPES/NaOH pH 7.2 buffer (10 ml), and stored at 
4°C. 
 
3.5.2.3 Determination of Non-covalent Binding 
 
To evaluate the purification procedure, an aliquot of the purified sample (1 ml) was 
incubated with 8M urea solution (1 ml) for 48 h at 4°C. Concentrated urea acts as 
a chaotropic agent and disrupts all non-covalent interactions. Here, it was used to 
separate non-covalently bound FITC from ß-galactosidase. Subsequently, the 
mixture was purified by gel filtration followed by determination of the concentration 
of both, the fluorophor and protein, in the eluates. 
 
3.5.3 Characterization of FITC-β-Galactosidase 
 
3.5.3.1 Micro BCA™ Assay 
 
The Micro BCA™ assay (Pierce, Illinois, USA) is a colorimetric assay for the 
quantification of protein. In alkaline environment, Cu+2 ions are reduced by protein 
and form Cu+1. Bicinchoninic acid (BCA) forms a purple-colored chelate with Cu+1, 
which exhibits a strong absorbance at 562 nm.  
Briefly, the sample solution (150 µl/well) was pipetted into a 96-well microplate. 
Upon addition of 150 µl of working reagent per well the plate was mixed on a plate 
shaker for 30 seconds and incubated for 2 h at 37°C. Finally, the absorbance was 
determined at 562 nm [4]. 
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3.5.3.2 Estimation of the Coupling Rate 
 
The coupling rate of FITC modified ß-galactosidase was arbitrary defined as the 
number of FITC molecules per ß-galactosidase molecule. The FITC-fluorescence 
was determined at 485nm/525nm (excitation/emission). The amount of 
immobilized FITC was calculated from a calibration curve and related to the 
protein content of the solution. 
 
3.6 Covalent Coupling of ß-Galactosidase to 
PLGA-Microparticles 
See Chapter 6 (Attachment A). 
 
3.7 Coupling of F-WGA and ß-Galactosidase to 
PLGA-Microparticles 
 
In order to prepare WGA-functionalized-galactosidase-grafted PLGA particles, two 
strategies were assessed. F-WGA was either coupled to already enzyme-modified 
particles, or the conjugation of WGA and enzyme were performed simultaneously. 
 
3.7.1 Coupling of F-WGA to β-Galactosidase-grafted 
PLGA-Microparticles 
 
For the covalent immobilization of F-WGA on enzyme-modified particles, the 
carbodiimide and the glutaraldehyde method were evaluated. 
 
3.7.1.1 Carbodiimide Method 
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1.25 ml β-Galactosidase-HMD -particle suspension were incubated with 250 µl of 
the EDAC/NHS solution to activate the carboxylate groups of the surface-coupled 
enzyme. After purification, 135 µg F-WGA were added and the mixture was 
incubated end-over-end at 4°C overnight. Subsequently, unreacted binding sites 
were saturated with glycine and purified by repeated washing. Finally, the particles 
were re-suspended in 1.25 ml 50mM MgSO4/20mM HEPES/NaOH pH 7.2. 
 
3.7.1.2 Glutaraldehyde Method 
 
12.5 µl 70% Glutaraldehyde solution were added to 1.25 ml 
β-galactosidase-HMD-particle suspension and incubated for 5 h at 4°C. Excess 
reagent was removed as described above. After addition of 135 µg F-WGA the 
suspension was incubated end-over-end at 4°C overnight. Subsequently, 
unreacted binding sites were saturated with glycine, purified and resuspended as 
mentioned above (3.7.1.1). 
 
3.7.2 Coupling of β-Galactosidase and F-WGA to 
HMD-modified Particles 
See Chapter 6 (Attachment A). 
 
3.8 Quantification of Particle-bound F-WGA 
See Chapter 6 (Attachment A). 
 
3.9 Binding of Modified Microparticles to Caco-2 
Cells 
See Chapter 6 (Attachment A) 
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4. Results and Discussion 
 
4.1 ß-Galactosidase from E. coli 
 
4.1.1 Enzymatic Assay 
 
For the determination of the activity of β-galactosidase, a colorimetric assay 
based on the enzymatic cleavage of ortho-Nitrophenyl-β-galactoside (ONPG) 
followed by photometric detection of the formed o-nitrophenolate was applied.  
For each measurement, a calibration curve was established. For this purpose, 
aliquots of a stock solution of E. coli β-galactosidase were stored at -80°C and 
processed immediately prior to use. (single data see chapter 7 attachment B figure 20, 
table 1) 
 
It was necessary to prepare the calibration curves in parallel, because the assay is 
strongly time dependent. After 60 min of incubation, the absorption approximately 
doubled as compared to 30 min of incubation (Figure 6). For the applied amounts 
of E. coli β-galactosidase an incubation time of 30 min was sufficient. For the 
analysis of β-galactosidase from Kluyveromyces lactis (Lactozym®) and 
β-galactosidase-grafted microparticles, however, the incubation time was 
extended to 120 min in order to increase the sensitivity of the assay. 
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Figure 6: Calibration graph of E.coli β-galactosidase after incubation for 30 min or 
60 min and readout at 410 nm. (single data see chapter 7 attachment B table 2) 
 
In order to determine the optimum detection wavelength spectral scans of ONPG 
and o-nitrophenolate were performed (Figure 7). At 410 nm, the o-nitrophenolate 
exhibited maximum absorption, while the absorption of ONPG was nearly at its 
minimum. Based on these results, in order to discriminate between the product 
o-nitrophenolate and the unreacted substrate ONPG, the absorption was 
determined at 410 nm. 
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Figure 7: Spectral scan of ONPG and o-nitrophenolate from 390 nm to 460 nm. 
 
4.1.2 Storage Stability 
 
Three different dilutions (10 µg/ml, 5 µg/ml, 1 µg/ml) of E. coli ß-galactosidase in 
25mM HEPES/NaOH pH 7.2 were prepared. To determine the effect of 
magnesium on the enzyme stability, three dilutions in 25mM HEPES/NaOH pH 7.2 
supplemented with magnesium (50mM MgSO4) were prepared in parallel. After 7 
and 14 days at 4°C, the enzyme activity was determined (Figure 8). After two 
weeks the main part of the enzyme activity was lost in both dilution series, with 
and without magnesium. Thus, under the employed conditions any beneficial 
effect of magnesium on the stability could not be observed. 
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Figure 8: Stability of β-galactosidase from E. coli in presence and absence of 
magnesium at three different enzyme concentrations (10 µg/ml, 5 µg/ml, 1 µg/ml). 
The enzyme activity is given as µg enzyme/ml. (single data see chapter 7 attachment B 
table 3) 
 
4.1.3 Protein Quantification 
 
In order to evaluate the FITC-labeling procedure of β-galactosidase, it was 
necessary to quantify the protein content of the eluates of gel filtration and affinity 
chromatography. At this, the micro BCA™ assay was applied. 
Commonly, BSA is used as a reference in this assay. Since the amino acid 
composition of a protein influences the extent to which Cu2+ is reduced to Cu1+ it 
might be more accurate to use the respective protein as a reference. Indeed, 
similar amounts (µg/ml) of BSA and ß-galactosidase from E. coli gave different 
results (Figure 9). Therefore, unmodified β-galactosidase was used as a reference 
for the determination of the enzyme content of the purified solutions after FITC 
modification.  
 
0
2
4
6
8
10
12
10µg/ml 5µg/ml 1µg/ml
µ
g
/m
l
First day with Mg
First day without Mg
7 day with Mg
7 day without Mg
14 day with Mg
14 day without Mg
RESULTS AND DISCUSSION 
30 
 
Figure 9: Micro BCA™ assay of known amounts of BSA and E. coli 
ß-galactosidase. (single data see chapter 7 attachment B table 4) 
 
4.1.4 Characterization of FITC-labeled ß-Galactosidase 
 
4.1.4.1 Fluorimetric Analysis  
 
To quantify the amount of enzyme-coupled as well as non-reacted fluorescein, the 
fluorescence intensity of the eluates was determined at 485 nm/525 nm. For 
comparison, a calibration curve with fluorescein sodium in 25mM HEPES/NaOH 
pH 7.2 was prepared. (single data see chapter 7 attachment B figure 21, table 5) 
 
The unbound FITC was removed by gel filtration. The eluate was collected in 20 
fractions. The fluorescence intensities in the different fractions are shown in Fig. 
10. As large molecules are eluted first, the peak (fractions 3 to 5) was attributed to 
FITC-modified ß-galactosidase. By contrast, FITC is a small molecule, which is 
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expected to be retarded. The fluorescence intensities in the later fractions ongoing 
from fraction 15 increased again, which might be due to free fluorescence. 
 
Figure 10: Fluorescence intensities of the eluate (20 fractions) after gel filtration of 
FITC-labeled ß-galactosidase determined at 485 nm/525 nm. 
 
4.1.4.2 Protein Quantification 
 
The protein content of the fractions was determined by Micro BCA™ assay, and 
calculated using a calibration curve prepared with E. coli β-galactosidase. (4.1.3). 
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Ongoing from both assays the ratio between fluorophor and protein (F/P ratio) 
was calculated which represents the number of immobilized flourescein molecules 
per ß-galactosidase molecule. On the one hand sufficient FITC should be coupled 
to the surface of ß-galactosidase to allow the detection of the labeled protein, on 
the other hand there should remain free coupling sites on the surface of the 
enzyme sufficient for immobilization at the particles. For this purpose, the optimum 
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ß-galactosidase were analyzed. The results depicted from Fig. 11 show that a 
higher FITC concentration (column A) results in a better F/P ratio than the lower 
concentration (column C). 
 
Magnesium is often added to β-galactosidase preparations to improve the enzyme 
stability. In order to assess a possible influence of magnesium on FITC-labeling, 
50mM MgSO4 was added during the FITC-ß-galactosidase coupling process. 
However, using the same proportion between FITC and enzyme, the F/P ratio 
decreased by about 40% in presence of magnesium (column B) as compared to 
that without magnesium (column A). To conclude, the most appropriate F/P ratio 
for our purpose was obtained applying coupling process without magnesium and a 
FITC concentration of 25 µg/mg enzyme. 
 
 
Figure 11: F/P ratio of FITC functionalized ß-galactosidase after gel filtration using 
two different concentrations of FITC (25 µg/mg, 8.33 µg/mg enzyme) with or 
without magnesium. 
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4.1.4.4 Determination of Non-covalent Binding 
 
In order to guarantee stable binding between FITC and ß-galactosidase, a 
covalent linkage is preferable. To assess contribution of non-covalent binding, the 
FITC-labeled enzyme was treated with 8M urea, which disrupts non-covalent 
bonds. 
In Fig. 12, three different purification processes are compared. The first column 
shows the F/P ratio of FITC-modified enzyme after gel filtration. The second 
column shows the ratio after two consecutive gel filtration processes. In the third 
column, the ratio is shown for FITC-labeled enzyme that was first purified by gel 
filtration, then incubated with the chaotropic agent, and finally purified by a second 
gel filtration. The results demonstrate that one gel filtration process was not 
sufficient to remove weakly bound FITC since less than one third of the fluorophor 
was bound covalently after a single size exclusion chromatography.  
 
 
Figure 12: Influence of the purification procedure on the amount of 
ß-galactosidase bound fluorescein (F/P-ratio) of two batches with different initial 
amounts of fluorophor (25 µg/mg, 8.33 µg/mg enzyme). 
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In summary, β-galactosidase was successfully labeled with FITC. For an optimal 
F/P ratio between one and two, which seems most appropriate for the further 
coupling steps, a FITC concentration of 25 µg/mg enzyme yielded favorable 
results. Interestingly, the addition of magnesium reduced the coupling efficiency. 
However, the subsequent purification procedure needs further improvements. To 
remove the non-covalently bound FITC one or two gel filtration steps were not 
sufficient as demonstrated by the use of the chaotropic agent. Moreover, as a 
main drawback, the enzyme solution is more and more diluted by multiple gel 
filtration steps, which makes the sole application of this chromatographic 
technique  inappropriate for further coupling to the particle surface. 
 
4.2 ß-Galactosidase from Kluyveromyces lactis 
(Lactozym
®
) 
 
In contrast to β-galactosidase from E.coli, the enzyme from Kluyveromyces lactis 
(Lactozym®) is generally recognized as safe (GRAS) by the FDA (USA) [1]. 
Therefore, β-galactosidase from Kluyveromyces lactis (Lactozym®) was used for 
the further work. 
 
4.2.1 Enzymatic Assay 
 
According to the specifications provided by the manufacturer, the Lactozym® 
solution contained ≥ 3000 U/ml. For all experiments with K. lactis lactase 
performed in this diploma thesis, the activity of the original solution was set to be 
3000 U/ml and dilutions thereof were used for calibration. (single data see chapter 7 
attachment B figure 22, table 6) 
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Evaluation of a possible impact of PLGA-microparticles on the enzymatic 
assay 
Unmodified PLGA-Microparticles were tested (see chapter 6 Attachment A) using 
three different concentrations (4 mg/ml, 2 mg/ml, 1 mg/ml) in order to detect an 
eventual influence on the enzyme assay. Actually, the presence of PLGA particles 
exerted no influence on the test. (single data see chapter 7 attachment B table 7) 
 
4.2.2 Protein Assay 
 
Lactozym® solution represents a stabilized preparation of β-galactosidase, which 
is stored at 4°C. Types and concentrations of stabilizers as well as total protein 
content are not communicated by the manufacturer. Traditional stabilization 
strategies involve the addition of glycerine, different metal salts, and protein. 
When Lactozym® solution is used for carbodiimide- or glutaraldehyde-mediated 
coupling, other proteins might also react and compete with the enzyme. Therefore, 
the total protein content of the original solution has to be quantified by a micro 
BCA™ assay. Additionally it is very likely that glycerol forms part of the commercial 
Lactozym® solution. Regarding the rather high viscosity of the preparation it might 
even be present in higher concentrations. However, glycerol is known to interfere 
with the micro BCA™ assay [2].  
Therefore, different purification strategies were assessed to remove glycerol from 
the original solution.  
 
4.2.3 Purification of Lactozym
®
 
 
In order to remove glycerol, the original Lactozym® solution was purified by gel 
filtration, dialysis, and affinity chromatography and the resulting purified enzyme 
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solutions were characterized in terms of protein content and enzymatic activity. 
 
Gel filtration 
0.5 ml Lactozym® solution was passed through a PD-10 desalting column using 
25mM HEPES/NaOH pH 7.2 for elution. 
 
Dialysis 
1 ml Lactozym® solution was dialyzed against 25mM HEPES/NaOH pH 7.2 buffer 
(500 ml). Within one week, the external buffer was changed five times. 
 
Affinity chromatography 
Different strategies are reported for elution of β-galactosidase from an 
APTG-agarose affinity matrix [3]. To meet optimum conditions, three different 
eluting buffers have been tested. Each time, 0.5 ml Lactozym® solution was 
applied onto 1 ml of APTG gel suspension filled in a column. For elution, 200mM 
lactose solution, borate buffer pH 10, and carbonate buffer pH 10 were assessed. 
 
a) Elution with 200mM lactose buffer 
β-Galactosidase binds to the substrate analogue APTG, which is immobilized on 
the matrix. As APTG and lactose compete for enzyme binding, high 
concentrations of lactose are apparently useful for enzyme elution. 
However, the enzymatic activity assay of the eluates revealed that there was no 
β-galactosidase activity detectable. One possible reason might be that the eluting 
effect of lactose was not strong enough. To elucidate this issue, yellow-colored 
FITC-β-galactosidase (E. coli) was loaded on the APTG matrix and eluted with the 
same lactose solution. While the gel matrix was visibly yellow-colored, the lactose 
eluates did not exhibit relevant fluorescence. Thus, this rather high amount of 
lactose seems to be not strong enough to disrupt the interaction between 
APTG-agarose and β-galactosidase.  
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b) Elution with 0.1M borate/NaOH buffer pH 10 
Another possibility to elute β-galactosidase from the APTG-matrix is the use of 
alkaline buffers. Upon elution with 0.1M borate/NaOH pH 10 the collected 
fractions have to be quickly neutralized in order to prevent protein denaturation. 
For this purpose, three different neutralization methods were assessed. The 
eluates were either supplemented with 4M HCl (35 µl acid per 0.5 ml fraction) 
immediately after elution, or diluted 100-fold with 25mM HEPES/NaOH buffer pH 
7.2, or directly collected in test tubes containing 1M HEPES/NaOH buffer pH 7.2. 
Unfortunately, for neither one of the neutralization methods enzyme activity was 
detectable in the eluates. It was assumed that boric acid destroys the active 
center of β-galactosidase. In order to evaluate a potentially harmful influence of 
the borate buffer on ß-galactosidase activity, five different dilutions of the original 
enzyme solution with the same buffer steps（500-, 1000-, 2000-, 5000-, and 
10,000- fold） were kept for two hours at 4°C, and finally neutralized with 4M HCl. 
Subsequently, the enzyme activity was totally lost. 
 
c) Elution with 0.8M Na2CO3/NaOH buffer pH 10  
According to the harmful effect of borate buffer on enzymatic activity, 0.8M 
Na2CO3/NaOH buffer pH 10 with an equal buffer capacity as boric acid was used 
for elution. The eluates were neutralized immediately by the use of test tubes that 
contained 1M HEPES/NaOH pH 7.2 buffer. Once again, no enzymatic activity was 
detected in the eluates.  
 
Not only the enzymatic activity, but also the protein content of the eluates was 
assessed by the Micro BCA™ test. However, most of the samples were not directly 
applicable for that assay. Lactose represents a strong reducing carbohydrate and 
therefore disturbs the assay. Additionally, high HEPES concentrations are not 
compatible with the Micro BCA™ test. Consequently, the enzyme eluates 
neutralized with 1M HEPES/NaOH pH 7.2 were diluted 40-fold with distilled water 
prior to the protein assay in order decreed the compatible concentration of 100mM 
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HEPES [2].  
 
There were pronounced differences in the protein recovery (mg protein per ml 
applied Lactozym® solution) between with the various purification methods. Affinity 
chromatography yielded the lowest recovery rate. While elution with borate buffer 
resulted in a recovered protein amount of 3.63mg per ml Lactozym®, carbonate 
buffer yielded even less (1.03mg per ml Lactozym®). An explanation for the low 
recovery rate might be overloading of the matrix with the applied amounts of 
enzyme so that part of the enzyme initially could not bind and was washed away. 
Although gel filtration showed the highest recovery rate with 21.9mg per ml 
Lactozym®, the enzyme solution was diluted at least threefold, which was not 
advantageous for further works such as coupling. Additionally, it should be 
mentioned that the dilutions necessary for the protein assay and the subsequent 
recalculation might multiply the error of the assay. Dialysis yielded 12.49 mg per 
ml Lactozym®. Nevertheless, no enzymatic activity was detectable after dialysis. 
This might be attributed to the lack of appropriate stabilizers in the exchange 
buffer.  
 
In summary, the presented experiments cannot provide a satisfying answer to the 
basic question about the total protein content of the original Lactozym® solution. 
Furthermore, the purification methods were not effective enough to prepare pure 
and active enzyme for coupling. This will be the subject of future studies. 
 
4.2.4 Storage Stability 
 
The stability of β-galactosidase from Kluyveromyces lactis was tested at 6 
different concentrations (20 U/ml, 15 U/ml, 10 U/ml, 5 U/ml, 2 U/ml, and 1 U/ml). 
The original solution (Lactozym®) was diluted with 50mM MgSO4 in 20mM 
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HEPES/NaOH pH 7.2, which is the same buffer as in β-galactosidase modified 
PLGA-suspension. The analysis of the enzyme activities on day 0, 1, 2, 7 and 28 
revealed a similar decrease as already observed in case of the 
β-galactosidase-PEI or -HMD modified particle suspension (see chapter 6 
Attachment A) (Figure 13). 
 
 
Figure 13: Stability of β-galactosidase from Kluyveromyces lactis. The 
β-galactosidase activity in given in units (U) per ml solution of diluted original 
product (Lactozym®). (single data see chapter 7 attachment B table 8) 
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4.3 Preparation and Characterization of 
PLGA-Microparticles 
 
4.3.1 Preparation of PLGA-Microparticles 
 
In the present diploma thesis, PLGA microparticles were prepared by spray-drying 
(see chapter 6 Attachment A). The yield of this process amounted to only 10 to 40% 
and there was a considerable proportion of aggregated particles. The drawbacks 
of spray-drying PLGA are the low glass transition temperature of PLGA, which is 
slightly above body temperature, and the low boiling points of appropriate solvents. 
PLGA is soluble in organic solvents like ethyl acetate, ethyl formate, acetone or 
methylene chloride. For the present study, the solvent with the lowest boiling point 
(40°C), methylene chloride, was used. However, the attempt to avoid 
temperatures higher than the glass transition temperature resulted in particles that 
still contain residual solvent when they reach the cyclone separator. These 
non-hardened particles can stick to the glass walls and reduce the yield. Moreover, 
they tend to form aggregates. When the temperature was increased in spite of that, 
the particles adhered to the walls as well. Elevating the temperature above the 
glass transition temperature seemed to produce sticky particles as well. However, 
those problems of poor yield might be overcome by using another type of spray 
dryer. A drying tower with a larger diameter might allow for more complete drying 
at moderate temperatures.  
SEM images of PLGA microparticles reveal a broad size distribution and the 
presence of some aggregates (Figure 14). 
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Figure 14: SEM image of spray dried PLGA-microparticles prior size fractionation.  
 
Out of this reasons, the particles were fractionated according to their size prior to 
surface modification (Figure 15) (see chapter 6 Attachment A). 
 
Figure 15: SEM image of spray-dried PLGA-microparticles after size fractionation. 
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4.3.2 Characterization of the PLGA-Microparticles 
 
The mean particle size and the size distribution can be determined by different 
methods. Image evaluation of microscopic images (see chapter 6 Attachment A) 
revealed a particle size of about 2 - 4 µm. This was confirmed by flow cytometric 
analyses (data not shown), whereas laser diffractometry pointed to bigger 
particles (Figure 16). According to laser diffraction analyses, about 50% of the 
particles were smaller than 4.6 µm and 90% were smaller than 10.3 µm. 
 
 
Figure 16: Size distribution after size fractionation as determined by laser 
diffractometry. 
 
However, the results obtained by the laser diffraction technique are 
volume-distributed. Therefore, smaller particles are underrepresented despite 
their potentially large number. By contrast, image evaluation and flow cytometry 
are based on measuring the characteristics of many single particles. 
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4.4 Coupling of ß-Galactosidase to 
PLGA-Microparticles 
 
4.4.1 Immobilization of K. lactis ß-Galactosidase Using 
Different Spacers 
See Chapter 6 (Attachment A). 
 
4.4.2 Effect of Coupling Reagent and Incubation Time 
 
In order to optimize ß-galactosidase coupling to HMD-modified particles 
(PLGA-HMD-c-Gal), different concentrations of EDAC/NHS and different 
incubation times were tested (Figure 17).  
The highest particle-bound enzymatic activity amounted to 12 U per ml particle 
suspension. It was achieved by using the highest concentration of EDAC/NHS 
("100%") and incubating overnight. Applying only one-tenth of the coupling 
reagents decreased the result by 25% (9 U/ml). A further reduction of activation 
reagents to only 1% of the highest amount resulted in a very low activity of only 1 
U/ml. Shortening the incubation time from overnight to 2 h resulted in a decrease 
of particle-bound enzymatic activity by two thirds (4 U/ml). The lowest activity (1 
U/ml) was observed after overnight incubation with 1% EDAC/NHS. Taken 
together, the best results were obtained with the highest concentration of reagents 
and the longest incubation time. 
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Figure 17: ß-Galactosidase activity in units (U) per ml suspension of 
PLGA-HMD-c-Gal particles. PLGA-HMD particles were activated at three different 
concentrations of EDAC/NHS and two different incubation times; 100% 
EDAC/NHS corresponds to 45 mg EDAC and 1.875 mg per 625 µl 
ß-galactosidase and 1.25 ml particle suspension each. (single data see chapter 7 
attachment B table 9) 
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4.5 Coupling of F-WGA and ß-Galactosidase to 
the PLGA-Microparticles 
 
4.5.1 Immobilization of F-WGA on β-Galactosidase-grafted 
PLGA-Microparticles 
 
4.5.1.1 Carbodiimide Method 
 
Fluorescein-labeled WGA was coupled to ß-galactosidase-HMD-modified PLGA- 
microparticles (PLGA-HMD-c-Gal) via the carbodiimide method (Figure 18). While 
the particle-bound activity amounted to 9.9 U/ml prior to F-WGA conjugation, it 
was only about 1 U/ml after the additional modification step. During the coupling 
procedure, the particle-bound enzyme was lost for the most part. Thus, F-WGA 
coupling using the carbodiimide reaction impaired the activity of ß-galactosidase. 
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Figure 18: ß-Galactosidase activity in units (U) per ml modified 
PLGA-microparticle suspension of F-WGA-PLGA-HMD-c-Gal microparticles. 
PLGA-HMD-c-Gal particles before and after carbodiimide-mediated F-WGA 
conjugation using four different F-WGA concentrations (135 µg, 13.5 µg, 1.35 µg, 
0 µg F-WGA per 625 µl ß-galactosidase and 1.25 ml particle suspension each). 
(single data see chapter 7 attachment B table 10) 
 
4.5.1.2 Glutaraldehyde Method 
 
As carbodiimide-mediated coupling of F-WGA impaired the activity of the 
particle-bound enzyme, F-WGA conjugation via glutaraldehyde was assessed. 
While the particle-bound activity was 8.6 U/ml before coupling, it decreased to 0.6 
U/ml after F-WGA coupling (Figure 19). In summary, this method was also not 
applicable for F-WGA-coupling to the enzyme-grafted microparticles.  
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Figure 19: ß-Galactosidase activity in units (U) per ml modified 
PLGA-microparticle suspension of WGA-PLGA-HMD-c-Gal microparticles. 
PLGA-HMD-c-Gal particles before and after glutaraldehyde-mediated F-WGA 
conjugation using 135 µg per 625 µl ß-galactosidase and 1.25 ml particle 
suspension each (single data see chapter 7 attachment B table 11). 
 
4.5.2 Coupling of β-Galactosidase and F-WGA to 
HMD-modified Particles 
 
The particle-bound enzyme activity as well as the amount of immobilized targeter 
was determined and the interaction of the targeted microparticles with Caco-2 cell 
monolayers was examined (see chapter 6 Attachment A). 
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5. Conclusion 
 
Aiming at a new bioadhesive lactase preparation, biodegradable polymeric 
microparticles were prepared and functionalized with microbial-derived 
ß-galactosidase and wheat germ agglutinin. 
At this, poly (D,L-lactide-co-glycolide) (PLGA) microparticles were manufactured 
by spray drying. To eliminate aggregates and submicron particles, a method for 
size fractionation was established, which relies on a combination of subsequent 
suspension and centrifugation steps. The resulting mean diameter of the particles 
used for surface modification amounted to 2.78 ± 1.05 µm. 
For surface modification, ß-galactosidase from Escherichia coli and 
Kluyveromyces lactis were tested. First of all, a colorimetric assay for the 
quantification of the enzymatic activity was established, which is based on the 
hydrolytic cleavage of 2-nitrophenyl β-D-galactopyranoside (ONPG) and the 
detection of the yellow-colored product o-nitrophenolate. A bicinochoninic acid 
assay was used for protein quantification. Fluorescent-labeled E. coli 
ß-galactosidase was prepared by FITC conjugation. Despite gel filtration, rather 
high amounts of non-covalently bound FITC remained in the enzyme fractions. An 
examination of the storage stability of E. coli ß-galactosidase in 25mM 
HEPES/NaOH pH 7.2 buffer revealed full loss of enzymatic activity within two 
weeks. Moreover, no stabilizing effect of magnesium was detected. 
Searching for a more stable alternative, lactase from K. lactis was assessed, 
which has the additional advantage to be generally recognized as safe (GRAS) by 
the FDA. At this, the commercial preparation Lactozym® was used. To remove any 
additives that potentially impair the coupling to the particle surface, affinity 
chromatography with APTG agarose was investigated. However, elution with a 
concentrated lactose solution was not successful, and elution with alkaline buffers 
was not applicable due to harmful effects on the enzyme activity. The identification 
CONCLUSION 
50 
of an appropriate purification method that combines high recovery rates and 
conserved enzyme activities will be the topic of future studies. 
Thus, untreated Lactozym® solution was applied for coupling to the surface of 
PLGA-microparticles. Three different spacers, i.e. hexamethylene diamine, 
6-aminocaproic acid, and branched polyethylene imine, were examined as well as 
two different types of coupling techniques, namely carbodiimide and 
glutaraldehyde chemistry. The highest particle-bound enzyme activities were 
obtained with hexamethylene diamine amounting to 1470 U per g PLGA and with 
polyethyleneimine amounting to 970 U per g PLGA, which compares favorably 
with commercial products. Upon particle storage at 4°C, 50% of the activity was 
retained after one week, and 25% (HMD) or 20% (PEI) of the initial activity directly 
after coupling were still preserved after four weeks. Under the same conditions, 
dilutions of the original Lactozym® solution showed a similar decrease. Thus, 
future work will focus on the evaluation of appropriate additives to the storage 
buffer to guarantee long-term stability. 
To prepare targeted enzyme-loaded microparticles, F-WGA was first coupled to 
already enzyme-functionalized particles. However, the resulting enzyme activity 
was severely impaired. Alternatively, WGA and enzyme were coupled 
simultaneously to hexamethylene diamine-modified PLGA particles. The resulting 
microspheres displayed an enzymatic activity of 780 U per g PLGA. Moreover, an 
in-vitro cell binding assay using Caco-2 cell monolayers showed significantly 
increased particle-cell interaction of WGA-decorated particles. 
The present study demonstrates the feasibility of PLGA microparticles that are 
surface-modified with active β-galactosidase and with WGA as a functional active 
targeter to enable an interaction with enterocytes and thereby an enhanced 
intestinal residence time. On this basis, a more convenient management of 
lactose intolerance might be possible. 
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Abstract 
Background: Peroral β-galactosidase preparations for the management of lactose 
intolerance need to be administered in huge amounts (1500 to 6000 Unit) immediately 
before or together with a lactose-containing meal. 
Aim: Therefore, this work was aimed to develop an innovative long-acting formulation 
based on biodegradable polymeric microcarriers that are functionalized with 
β-galactosidase and targeted with wheat germ agglutinin (WGA) for bioadhesion and thus 
prolonged residence time in the small intestine. 
Methods: Spray-dried poly (D,L-lactide-co-glycolide) (PLGA) particles with 2.78 ± 1.05 
µm in diameter were functionalized with β-galactosidase from Kluyveromyces lactis and 
WGA using different types of spacers (polyethyleneimine, hexamethylene diamine, 
6-aminocaproic acid) and coupling methods (carbodiimide, glutaraldehyde). The 
particle-bound enzyme activity was determined and the interaction with Caco-2 cell 
monolayers was assessed. 
Results: Up to 1470 Units β-galactosidase per gram PLGA were immobilized. The best 
results were obtained with hexamethylene diamine as a spacer applying the carbodiimide 
method. At this, a nearly 6-fold increase in enzyme activity was obtained as compared to 
particles without spacer. Upon targeting with WGA, binding to artificial human intestinal 
epithelium was increased considerably. 
Conclusions: WGA-targeted PLGA microparticles for the delivery of β-galactosidase 
were prepared, which are promising candidates for a convenient biomimetic treatment 
regimen of lactose intolerance. 
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1 INTRODUCTION 
 
Globally, the majority of people continuously lose the ability to produce lactase 
(lactase-phlorizin hydrolase; LPH; β-galactosidase) after weaning. The prevalence of 
lactase deficiency coincides with the ethnic background reaching from 2-15% among 
northern Europeans to nearly 100% among Asians.
1
 LPH is located at the brush border of 
enterocytes
2, where it catalyzes the hydrolytic cleavage of β-galactose-1,4-glucose 
(lactose) to galactose and glucose. In absence of enzyme, lactose cannot be digested in the 
small intestine and it reaches the colon, where it increases the osmotic pressure and pulls 
water into the gut lumen. Moreover, it is fermented by colon bacteria, which may lead to 
increased production of intestinal gas and potentially toxic metabolites. When lactose 
ingestion induces clinical symptoms, which are gut-related such as abdominal pain, bowel 
distension, and flatulence or even systemic like headache, loss of concentration, and 
muscle pain, lactose maldigestion is referred to as lactose intolerance.
1,3
 
Lactose is not only present in milk at 5% (w/v), but also in a broad range of dairy 
products and processed foods, such as ice cream or even salad sauces and sausages, as 
well as pharmaceuticals. Milk and whey can be industrially treated with lactase in order 
to reduce their lactose content.
4-5
 Although an increasing variety of such pre-treated 
low-lactose dairy products is available, it is still often inconvenient for affected persons to 
avoid the uptake of lactose in amounts that might provoke symptoms of intolerance. 
Moreover, omitting dairy products has the disadvantage of losing a major source of 
calcium and proteins. A well-established strategy for the management of lactose 
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intolerance is peroral lactase substitution with capsules or tablets containing 
microbial-derived β-galactosidase preparations. They have proven successful in reducing 
the severity of symptoms caused by lactose uptake in a dose-dependent manner.
6-7
 
However, they are only effective when administered immediately before or together with 
the lactose-containing meal. 
Therefore, the aim of this work was to develop an innovative long-acting alternative 
formulation, which allows for a reduced dosing frequency and higher patient compliance. 
For this purpose, microparticles from the biocompatible, biodegradable and 
FDA-approved polymer poly (D,L-lactide-co-glycolide) (PLGA) were prepared
8
 and 
functionalized with β-galactosidase and wheat germ agglutinin (WGA). The choice of the 
microbial source for β-galactosidase mainly depends on the required pH optimum of the 
enzyme
4
 and the pH in the target region. As the physiological pH in the small intestine 
ranges from slightly acidic conditions to about pH 7.5, the enzyme from Kluyveromyces 
lactis was chosen, which exhibits optimum activity at pH 7.0-7.5.
9
 Moreover, it is 
generally recognized as safe by the FDA.
10
 The dietary lectin WGA, which is derived 
from Triticum vulgare, was used as a targeter. It specifically binds to 
N-acetyl-D-glucosamine and sialic acid, which form part of the gastrointestinal mucus 
and the glycocalyx of human intestinal epithelial cells.
11-12
 WGA-grafted particles are 
already known to attach to the mucus and the epithelium of the small intestine.
8,13-14
 For 
the work presented, WGA-targeted β-galactosidase-loaded carriers were prepared, which 
should be retained near the brush border, i.e. in exactly those regions of the 
gastrointestinal tract where physiological lactase would occur and exerts its action. 
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2 MATERIALS AND METHODS 
 
2.1 Materials 
 
Resomer RG502H (PLGA, 50:50 lactide/glycolide) was purchased from Boehringer 
Ingelheim (Ingelheim, Germany). β-Galactosidase from Kluyveromyces lactis 
(Lactozym
®; ≥ 3000 U/ml), and glutaraldehyde solution (70% in H2O) were obtained 
from Sigma Aldrich (Vienna, Austria). Fluorescein-labeled wheat germ agglutinin 
(F-WGA, molar ratio fluorescein/protein = 2.9) was bought from Vector Laboratories 
(Burlingame, USA). Polyethyleneimine (PEI, branched, MW 1200) was purchased from 
Polysciences (Warrington, USA). All other chemicals were of analytical purity and 
obtained from Sigma Aldrich. 
 
2.2 Preparation of PLGA microparticles 
 
PLGA microparticles were prepared by spray-drying as previously described
8,14
 and 
fractionated according to their size. Briefly, a 6.5% (w/v) solution of PLGA in methylene 
chloride was spray-dried with a Mini Spray Dryer B-191 (Buechi Labortechnik AG, 
Flawil, Switzerland). 100 mg spray-dried particles were suspended in 10 ml distilled 
water by ultrasonication. Remaining aggregates and larger particles were spun down for 2 
min at 400 rpm. To remove submicron particles, the supernatant was further centrifuged 
for 10 min at 3200 rpm and the pellet was re-suspended in 5 ml distilled water. The PLGA 
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content was determined gravimetrically after lyophiliziation of an aliquot. For further 
processing the suspension was centrifuged again (3500 rpm, 10 min, 4°C) and the pellet 
was re-suspended in 20mM HEPES/NaOH pH 7.0 at a concentration of 10 mg PLGA/ml. 
The mean particle size was determined by measuring the diameter of 200 particles after 
microscopic inspection using Lucia Gv5.0 software for image evaluation. 
 
2.3 Covalent coupling of β-galactosidase and F-WGA 
 
Following different strategies, the surface of PLGA microparticles was functionalized 
with β-galactosidase and fluorescent-labeled WGA. Each approach was assessed in 
triplicate. 
 
2.3.1 Activation of PLGA carboxylate groups via the carbodiimide method 
1.25 ml particle suspension (10 mg/ml in 20mM HEPES/NaOH pH 7.0) were activated 
by addition of 250 µl of a freshly prepared solution of 1-ethyl-3(3-dimethylaminopropyl) 
carbodiimide (EDAC) and N-hydroxysuccinimide (NHS) (180 mg/ml EDAC and 7.5 
mg/ml NHS in 20mM HEPES/NaOH pH 7.0) and end-over-end incubation for 2 h at 
room temperature. Excess reagents were removed by centrifugation (3500 rpm, 10 min, 
4°C) followed by re-suspension in 1.875 ml of 15mM lactose/50mM MgSO4/20mM 
HEPES/NaOH pH 7.4. After a second centrifugation step, the pellet was suspended in 625 
µl of fresh buffer. 
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2.3.2 Modification of the particle surface with different spacers  
For the introduction of spacers, 625 µl PEI (10 mg/ml in 1M HEPES/NaOH pH 7.2), 625 
µl hexamethylene diamine (HMD; 20 mg/ml in 1M HEPES/NaOH pH 7.2), or 625 µl 
6-aminocaproic acid (ACA; 10 mg/ml in 50mM MgSO4/20mM HEPES/NaOH pH 7.2) 
solution were added to the activated particle suspension (2.3.1) and incubated 
end-over-end overnight at room temperature. Excess spacer was removed by three 
washing steps including centrifugation (3500 rpm, 10 min, 4°C) and re-suspension in 
1.875 ml 20mM HEPES/NaOH pH 7.0. Subsequently, the pellet was suspended in 625 µl 
of the same buffer. 
 
2.3.3 Coupling of β-galactosidase to the particle surface without a spacer 
After addition of 625 µl Lactozym
®
 solution, the activated microparticles (2.3.1) were 
allowed to react overnight at 4°C. Unreacted binding sites were saturated by incubation 
with 250 µl of 100 mg/ml aqueous glycine solution for 30 min at 4°C. Subsequently, the 
suspension was purified by repeated centrifugation (3500 rpm, 10 min, 4°C) and 
re-suspension in fresh buffer. For the first two washing steps 1.875 ml 15mM 
lactose/50mM MgSO4/20 mM HEPES/NaOH pH 7.2 were used as a buffer. In order to 
avoid any interference with the enzyme activity assay, lactose free buffer was applied for 
the last two washing steps. Finally, the particles were suspended in 1.25 ml of 50mM 
MgSO4/20mM HEPES/NaOH pH 7.2 and stored at 4°C until use. 
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2.3.4 Coupling of β-galactosidase to ACA-modified particles via the carbodiimide 
method 
The carboxylate groups of the immobilized 6-aminocaproic acid (2.3.2) were activated 
using 250 µl of the EDAC/NHS solution as described above (2.3.1). After purification, 
625 µl Lactozym
®
 solution were added for conjugation via enzyme amine groups, and the 
suspension was further treated as mentioned above (2.3.3). 
 
2.3.5 Coupling of β-galactosidase to PEI- and HMD-modified particles via the 
carbodiimide method 
In order to activate enzyme carboxylate groups, 625 µl Lactozym
®
 solution were mixed 
with 250 µl EDAC/NHS solution (2.3.1) at 4°C. After addition to the spacer-grafted 
microparticles (2.3.2) the mixture was rotated overnight at 4°C to allow for a reaction 
with the amine groups of the spacer. Finally, excess binding sites were blocked, and the 
suspension was purified (see 2.3.3). 
 
2.3.6 Coupling of β-galactosidase to PEI- and HMD-modified particles via 
glutaraldehyde 
12.5 µl 70% aqueous glutaraldehyde were added to PEI- and HMD-coupled particles 
(2.3.2) and incubated for 5 h. After removal of excess reagent as described above (2.3.1) 
625 µl Lactozym
®
 solution were added to the suspension and the mixture was kept 
overnight at 4°C on a rotator, saturated with glycine and purified as above (2.3.5).  
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2.3.7 Coupling of β-galactosidase and F-WGA to HMD-modified particles 
Different amounts of Lactozym
®
 (625 µl; 312.5 µl) were mixed with 27 µl F-WGA (5 
mg/ml), adjusted to 652 µl with 20mM HEPES/NaOH pH 7.2 and combined with 250 µl 
EDAC/NHS solution (2.3.1). This solution was added immediately to HMD-grafted 
PLGA microparticles (2.3.2) and incubated end-over-end at 4°C overnight. Subsequently, 
remaining binding sites were blocked and the suspension was purified extensively (2.3.5). 
Reference samples were prepared accordingly but omitting WGA. 
 
2.4 Activity assay of β-galactosidase 
 
The β-galactosidase activity was determined by a modified assay based on the enzymatic 
cleavage of 2-nitrophenyl β-D-galactopyranoside (ONPG) and the colorimetric detection 
of the resulting yellow o-nitrophenolate.
15
 Each well of a 96-well plate was filled with 5 
µl of a solution containing β-galactosidase and 50 µl working buffer (5 mM 
MgSO4/20mM HEPES/NaOH pH 7.2). Upon addition of 100 µl ONPG solution (14mM 
in distilled water) the mixture was incubated for 2 h at 37°C. Finally, 50 µl stop buffer 
(250mM HEPES/NaOH pH 9) were added and the absorption was read at 410 nm. 
Particle-bound enzyme activity was determined by end-over-end incubation of 200 µl 
particle suspension, 20 µl working buffer, and 400 µl ONPG solution (14mM in distilled 
water) in a test tube for 2 h at 37°C. After addition of 200 µl stop buffer, the suspension 
was centrifuged (5 min, 10000 rpm, 4°C), 205 µl of the supernatant were transferred into 
a 96-well plate and the absorption was determined at 410 nm. Each time, freshly prepared 
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dilutions of β-galactosidase in working buffer were measured in parallel, and the resulting 
calibration curve was used for calculation. The enzymatic activity of the particle 
suspension was determined immediately and after storage at 4°C for 1, 2, 7, 14, and 28 
days. For comparison, the activity of β-galactosidase (1 - 20 U/ml) kept in the same 
buffer at 4°C was determined at the same intervals.  
 
2.5 Quantification of particle-bound F-WGA 
 
Aliquots (35 µl) of the F-WGA modified particle suspensions were hydrolyzed with 315 
µl 0.2M NaOH. In a microplate, a triplicate of 100 µl/well was analyzed at 485/525 nm 
and the amount of immobilized F-WGA was determined using a calibration curve 
established with soluble F-WGA. 
 
2.6. Binding of surface-modified microparticles to Caco-2 cells 
 
160 µl/well cell suspension each containing 17 000 Caco-2 cells (DSMZ, Braunschweig, 
Germany) were seeded into a 96-well microplate. After 7 days, the confluent monolayers 
were incubated with 100 µl of a suspension containing either 
HMD/β-galactosidase-modified particles or HMD/β-galactosidase/F-WGA-functionalized 
carriers in 20mM isotonic HEPES/NaOH pH 7.4 for 1 h at room temperature under 
moderate shaking. Subsequently, the cells were washed five times with 200 µl of 20mM 
isotonic HEPES/NaOH pH 7.4 each, followed by addition of 50 µl of the same buffer to 
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each well. To assess the optical density of the cell layer with associated particles, the 
absorption at 600 nm was determined using a microplate reader (Infinite 200, Tecan 
Group Ltd., Grödig, Austria). Finally, these cells were imaged using light microscopy. 
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3 RESULTS AND DISCUSSION 
 
3.1 Preparation of PLGA microparticles 
 
After size fractionation the mean diameter of the spray-dried PLGA microparticles 
amounted to 2.78 ± 1.05 µm. This seems to be a reasonable particle size range for the 
required application: small enough to offer a large total surface area for high enzyme 
loading, and big enough to remain in the intestinal lumen and avoid cellular uptake. As to 
Desai et al., submicron particles are absorbed to a much higher extent than carriers in the 
micrometer range.
16
 For these reasons, significantly larger and smaller particles were 
removed in advance. Another advantage of administering microparticles is their short 
gastric residence time. Particles below 3 mm leave the stomach together with the fluid 
stream without remarkable retention time. Therefore, they are exposed to the acidic 
gastric juice for only a very short time.  
 
3.2 Immobilization of β-galactosidase using different spacers 
 
In order to guarantee the interaction between the enzyme and its substrate, 
β-galactosidase was not incorporated into the particle matrix, but immobilized at the 
particle surface. At this, the enzyme was coupled to PLGA carboxylate groups either 
directly or via different spacers (Figure 1). For enzyme immobilization at the particle 
surface without any spacer, the PLGA carboxylates were activated with carbodiimide and 
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allowed to react with the primary amine groups of β-galactosidase. Thereby, a 
particle-bound enzyme activity of 2.5 U per ml particle suspension was obtained 
(PLGA-c-Gal). However, these results were outperformed up to 6-fold when using a 
spacer: The linear spacer hexamethylene diamine (PLGA-HMD-c-Gal) increased the 
particle-bound activity nearly 6-fold (14.7 U/ml), while the increase was 4-fold (9.7 U/ml) 
in case of PEI (PLGA-PEI-c-Gal). Only 6-aminocaproic acid (PLGA-ACA-c-Gal) 
yielded a lower activity than without spacer. Besides different spacers, two different 
chemical procedures for the immobilization of β-galactosidase involving different sites of 
the enzyme were applied. While the highest activities were found when the enzyme was 
coupled via its carboxylate group to the amine groups of surface-immobilized HMD or 
PEI using the carbodiimide method, there was no benefit in using a spacer when the 
enzyme was conjugated via its amine groups. Neither coupling of β-galactosidase to the 
carboxylate groups of ACA-modified particles via the carbodiimide method 
(PLGA-ACA-c-Gal), nor conjugation to the amine groups of HMD (PLGA-HMD-g-Gal) 
or PEI (PLGA-PEI-g-Gal) applying glutaraldehyde was successful. Thus, either the 
carboxylate groups of β-galactosidase seem to be better accessible for conjugation than its 
amine groups or the activity of the enzyme might be affected to a lesser extent by the 
coupling procedure. 
Interestingly, the activity of β-galactosidase coupled PEI-modified microparticles 
(PLGA-PEI-c-Gal) was lower than that of HMD-particles (PLGA-HMD-c-Gal), although 
branched polyethyleneimine offers multiple primary amine groups per molecule whereas 
hexamethylene diamine provides only one free amine group for coupling. Thus, the lower 
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activity in case of PEI might not be due to a smaller amount of coupled β-galactosidase, 
but to a harmful microenvironment that restricts the activity of the immobilized enzyme. 
The pH optimum of β-galactosidase from Kluyveromyces lactis is in the neutral range, but 
due to its numerous amine groups PEI might create an alkaline microenvironment thus 
constraining the enzyme activity.
9
 
The stability of the carrier-bound β-galactosidase was examined by enzyme assays after 
storage at 4°C for defined time intervals. For PEI- (PLGA-PEI-c-Gal) and HMD- 
(PLGA-HMD-c-Gal) modified particles, the activity decreased by about a third after one 
day. After one week, about half of the initial activity was retained, and after 4 weeks, it 
decreased to one fifth (PEI) or one quarter (HMD) of the initial values. Concerning 
storage stability, most favourable results were obtained without any spacer (PLGA-c-Gal). 
For comparison, the original β-galactosidase solution (Lactozym®) was diluted in the 
same buffer that had been used for storage of the particles. Thereby, the activity of the 
dilutions decreased by a similar extent as observed for the particle suspensions (data not 
shown).  
To elicit a therapeutic effect, high amounts of active β-galactosidase are necessary. Single 
doses of lactase usually contain between 1500 and 6000 U.
6
 The highest activity obtained 
in the presented study was 14.7 U/ml for a suspension that contained 10 mg/ml PLGA 
particles. This corresponds to 1470 U/g polymer, which compares favorably with 
commercial products. 
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3.3 Immobilization of β-galactosidase and F-WGA 
 
For targeted delivery to the small intestine, wheat germ agglutinin was used which offers 
the advantage to lose its carbohydrate-binding capacity in acidic environment.
12
 Therefore, 
the gastric passage of the particles will be unhampered, and they can rapidly attain the 
small intestine, where WGA binds to the mucus and the glycocalyx of enterocytes. 
Furthermore, it is most unlikely that WGA interacts with nutritional components. In 
preliminary assays, WGA was conjugated to β-galactosidase grafted microparticles 
(PLGA-HMD-c-Gal). However, the resulting particles exerted negligible enzymatic 
activity. As an alternative approach, both fluorescent labeled WGA and β-galactosidase 
were activated concurrently and conjugated to HMD-grafted PLGA microcarriers. 
Fluorimetric analysis revealed that 0.5765 ± 0.1040 µg/ml F-WGA were immobilized 
together with β-galactosidase. Reducing the amount of β-galactosidase for coupling to 50% 
doubled the lectin-coupling efficiency yielding 1.1607 ± 0.1634 µg/ml F-WGA. Whereas 
application of half of the enzyme resulted in half enzyme immobilisation efficiency, there 
were only slight differences between the enzyme activities in presence and absence of 
WGA. In addition, there was no negative influence of WGA on the storage stability of the 
enzyme. 
Furthermore, it is most likely that the proteins were not only coupled to the spacer, but 
also crosslinked. As long as their functionality is not impaired by chemical modification 
of the binding site or by steric hindrance, this represents no drawback. Lactose is a small 
molecule, which can diffuse to the active sites of β-galactosidase even if the enzyme is 
ATTACHMENT A MANUSCRIPT 
67 
not antenarry exposed at the microparticle. By contrast, the WGA coupling position is 
essential for targeting, because it has to interact with the corresponding carbohydrate 
moieties of the mucus or the glycocalyx. While fluorimetry allowed to quantify the 
amount of immobilized fluorescent-labeled WGA, its effectiveness as a targeter was 
assessed by cell interaction studies. 
 
3.4 Cytoadhesion 
 
To study the cytoadhesive properties of the modified particles, Caco-2 cells were used, 
which represent a recognized model for the human intestinal epithelium. Caco-2 
monolayers were incubated with carriers that were either decorated with β-galactosidase 
alone or with the enzyme and WGA. After removing unbound particles by repeated 
washings, the optical density of the monolayers was determined at 600 nm. While plain 
monolayers yielded an OD600 of 0.0998 ± 0.0006, enzyme-functionalized particles 
enhanced the OD600 by 0.0424 ± 0.0097. In case of WGA-functionalized particles the 
increase amounted to 0.0791 ± 0.0127. The almost doubled OD600 values point to a 
considerable increase of cell-bound particles in presence of WGA. This observation of 
significantly higher binding of WGA-grafted particles to epithelial cells as compared to 
non-targeted particles was also supported by microscopic images (Figure 3). 
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4 CONCLUSION AND OUTLOOK 
 
β-Galactosidase was covalently conjugated to the surface of biodegradable polymeric 
microparticles with a mean diameter of 2.78 ± 1.05 µm. As highest particle-bound 
enzymatic activities were observed when using hexamethylene diamine (1470 U/g PLGA) 
and polyethyleneimine (970 U/g PLGA) as a spacer, it might be concluded that 
immobilization via enzyme carboxylate groups is preferable. After storage for one week 
at 4°C, about half of the activity was retained, and after four weeks, the beads yielded still 
one quarter (HMD) or one fifth (PEI) of the original activity. However, marketed products 
tested under the same conditions revealed similar results. Thus, improved storage stability 
might be achieved by addition of appropriate stabilizers. Immobilisation of both 
β-galactosidase and WGA significantly enhanced particle binding to Caco-2 cell 
monolayers, which represent a model for the human intestinal epithelium. 
To conclude, the presented drug delivery system is a promising approach towards a more 
convenient management of lactose intolerance, since it mimics the physiological situation 
in healthy individuals. Similar to the natural localization of LPH at the brush border of 
enterocytes, WGA might mediate binding of the enzyme preparation to the mucus or the 
glycocalyx of the enterocytes, which should significantly prolong the residence time in 
the intestine. Ongoing from the presented data this biomimetic regimen merits further 
examination by in vivo studies. 
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FIGURE LEGENDS 
 
Figure 1. 
β-Galactosidase activity in units (U) per ml modified PLGA microparticle suspension. 
The particles were grafted with (PEI, HMD, ACA) or without spacer, β-galactosidase was 
immobilized via the carbodiimide method (c) and the glutaraldehyde (g). (n=3, mean  
SD) 
 
Figure 2. 
β-Galactosidase activity in units (U) per ml modified PLGA microparticle suspension. 
The particles were coupled with HMD as a spacer and β-galactosidase at two different 
concentrations was immobilized in presence or absence of F-WGA. (n=3, mean  SD) 
 
Figure 3. 
Caco-2 cell monolayers incubated with β-galactosidase- (A) and β-galactosidase/WGA- 
(B) functionalised PLGA microparticles. 
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FIGURES 
 
Figure 1 
 
ATTACHMENT A MANUSCRIPT 
74 
Figure 2 
 
0
1
2
3
4
5
6
7
8
9
10
U/ml
Day 0
Day 1
Day 2
Day7
Day 14
Day 28
ATTACHMENT A MANUSCRIPT 
75 
Figure 3 
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7. Attachment B 
 
B 1. ß-Galactosidase from E. coli 
 
B 1.1 Enzymatic Assay 
 
Table 1: Calibration curve at 410 nm after30 min incubation. 
Enzyme concentration (µg/ml) Absorption Units 
5 1.0295 
2.5 0.5061 
1 0.1857 
0.5 0.0987 
0 0.0000 
 
Figure 20: Calibration graph at 410nm upon with 30 min incubation. 
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Table 2: Calibration curve at 410 nm after 30 min and 60min incubation. 
Enzyme concentration (µg/ml) 
Absorption units 
(30 min) 
Absorption units 
(60 min) 
5 1.0295 2.2415 
2.5 0.5061 1.1205 
1 0.1857 0.4424 
0.5 0.0987 0.2068 
0 0.0000 0.0000 
 
B 1.2 Storage Stability 
 
Table 3: Stability of ß-galactosidase in presence and absence of magnesium as indicated by the 
enzyme activity (U/ml). 
Storage time 
  
ß-Galactosidase concentration (µg/ml) 
10µg/ml 5µg/ml 1µg/ml 
First 
day 
with Mg 9.69 5.05 1.55 
without 
Mg 
10.2 5.04 1.68 
7 day 
with Mg 8.84 3.98 1.01 
without 
Mg 
8.94 3.96 1.05 
14 day 
with Mg 0.16 0.19 0.18 
without 
Mg 
0.19 0.16 0.14 
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B 1.3 Protein Quantification 
 
Table 4: Calibration of the Micro BCA
™
 Assay using BSA (bovine serum albumin) and 
ß-galactosidase from E. coli (562nm). 
Protein  concentration (µg/ml) 
Absorption units 
(E.coli) 
Absorption units 
(BSA) 
40 0.2195 0.4656 
20 0.1085 0.1997 
10 0.0550 0.0734 
5 0.0231 0.0394 
2.5 0.0121 0.0103 
0 0.0000 0.0000 
 
B 1.4 Characterization of FITC-labeled ß-Galactosidase 
 
Table 5: Calibration of fluorescein-Na diluted in 25mM HEPES/NaOH pH 7.2 at 485 nm/525 nm. 
Fluorescein-Na (µg/ml) Fluorescence intensity 
0.1 35005.0 
0.05 17856.3 
0.025 8834.6 
0.0125 4393.0 
0.01 3501.3 
0 0.0 
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Figure 21: Calibration graph of fluorescein-Na in 25mM HEPES/NaOH pH 7.2 at 485 nm/525 nm. 
 
 
B 2 β-Galactosidase from Kluyveromyces lactis (Lactozym®) 
 
B 2.1 Enzymatic Assay 
 
Table 6: Calibration of ß-Galactosidase upon incubation for 120 min and reading at 410nm. 
ß-Galactosidase (µg/ml) Absorption units 
24 1.0180 
12 0.3105 
6 0.0984 
3 0.0327 
1.5 0.0111 
0.6 0.0051 
0.3 0.0019 
0 0.0000 
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Figure 22: Calibration graph of ß-Galactosidase upon incubation for 120 min incubation and 
readout at 410nm. 
 
 
Table 7: Evaluation of a possible impact of PLGA-microparticles on the enzymatic assay. 
 
Absorption units at 410nm 
Concentration of particle suspension 60 min incubation 120 min incubation 
4mg/ml 0.0911±0.0068 0.0693±0.0077 
2mg/ml 0.0709±0.0035 0.0685±0.0037 
1mg/ml 0.0679±0.0084 0.0754±0.0003 
Blank 0.0803±0.0097 0.0667±0.0102 
 
B 2.2 Storage Stability 
Table 8: Stability of β-galactosidase Lactozym
®
. 
β-galactosidase Lactozym
®
 (U/ml) Day0 Day1 Day2 Day7 Day14 Day28 
20 20.49 13.58 13.69 14.65 10.36 10.15 
15 16.27 10.55 10.47 10.91 7.82 7.69 
10 10.99 6.98 6.80 7.10 4.81 4.72 
5 6.01 3.51 3.40 3.43 2.16 2.10 
2 2.82 1.43 1.39 1.42 1.00 0.89 
1 1.53 0.63 0.55 0.69 0.65 0.46 
y = 0.0014x2 + 0.0089x - 0.0026
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B 3 Coupling of ß-Galactosidase to PLGA-Microparticles 
 
Table 9: Influence of coupling reagent and incubation time on enzyme activity (U/ml). 
 
U/ml particle suspension standard deviation 
100% EDAC/NHS overnight 12.17 0.23 
100% EDAC/NHS 2 hours 4.13 1.33 
10% EDAC/NHS overnight 9.07 1.28 
1% EDAC/NHS overnight 1.30 0.15 
 
B 4 Coupling of F-WGA and ß-Galactosidase to 
PLGA-Microparticles 
 
Table 10: Carbodiimide method – influence of WGA on enzyme activity (U/ml). 
 
U/ml particle suspension Standard deviation 
100% F-WGA 0.86 0.19 
10% F-WGA 1.08 0.64 
1% F-WGA 1.22 0.26 
0% F-WGA 1.59 0.82 
blank 9.85 0.13 
 
Table 11: Glutaraldehyde method – influence of WGA on enzyme activity (U/ml). 
 
U/ml particle suspension Standard deviation 
Blank 8.6051 0.1709 
F-WGA-galactosidase modified particles 0.6155 0.1274 
 
GERMAN ABSTRACT - ZUSAMMENFASSUNG 
82 
8. German Abstract - Zusammenfassung 
 
Ausgangspunkt: Perorale β-Galactosidase-Zubereitungen zur Behandlung der 
Laktoseintoleranz müssen in hohen Dosen (1500 bis 6000 Unit) unmittelbar vor 
oder gemeinsam mit Laktose-haltiger Nahrung verabreicht werden. 
Ziel: Das Ziel der vorliegenden Arbeit war daher die Entwicklung einer innovativen 
Formulierung mit länger anhaltender Wirkung basierend auf bioabbaubaren 
Polymer-Mikropartikeln, die mit β-Galactosidase und mit Weizenkeimagglutinin 
(WGA) als bioadhäsivem Targeter gekoppelt werden, um eine längere Verweilzeit 
im Darm zu erreichen. 
Methoden: Sprühgetrocknete Poly(D,L-lactid-co-glycolid) (PLGA) Partikel mit 
einem Durchmesser von 2,78 ± 1,05 µm wurden mithilfe verschiedender Spacer 
(Polyethylenimin, Hexamethylendiamin, 6-Aminocapronsäure) und verschiedener 
Kopplungsmethoden (Carbodiimid, Glutaraldehyd) mit β-Galactosidase von 
Kluyveromyces lactis und WGA funktionalisiert. Die partikelgebundene 
Enzymaktivität sowie die Interaktion mit Caco-2-Zell-Monolayern wurde 
untersucht. 
Ergebnisse: Es wurden bis zu 1470 Unit β-Galactosidase pro Gramm PLGA 
immobilisiert. Die besten Ergebnisse wurden unter Verwendung von 
Hexamethylendiamin als Spacer mit der Carbodiimidmethode erreicht. Dabei 
wurde beinahe sechsmal so viel aktives Enzym gekoppelt wie in Abwesenheit 
eines Spacers. Durch das immobilisierte WGA wurde die Bindung an künstliches 
humanes Darmepithel deutlich erhöht. 
Zusammenfassung: Als vielversprechender neuer Ansatz für eine 
patientenfreundliche biomimetische Behandlung der Lactoseintoleranz wurden 
WGA-gekoppelte β-Galactosidase-beladene PLGA-Mikropartikel erfolgreich 
hergestellt. 
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